These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35241571)

  • 1. Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage.
    van den Bosch A; Fransen N; Mason M; Rozemuller AJ; Teunissen C; Smolders J; Huitinga I
    Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35241571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis.
    Yik JT; Becquart P; Gill J; Petkau J; Traboulsee A; Carruthers R; Kolind SH; Devonshire V; Sayao AL; Schabas A; Tam R; Moore GRW; Li DKB; Stukas S; Wellington C; Quandt JA; Vavasour IM; Laule C
    Mult Scler Relat Disord; 2022 Jan; 57():103366. PubMed ID: 35158472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis.
    Luchetti S; Fransen NL; van Eden CG; Ramaglia V; Mason M; Huitinga I
    Acta Neuropathol; 2018 Apr; 135(4):511-528. PubMed ID: 29441412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light.
    Orsi G; Cseh T; Hayden Z; Perlaki G; Nagy SA; Giyab O; Olsen DA; Madsen JS; Berki T; Illes Z
    Mult Scler Relat Disord; 2021 Jun; 51():102923. PubMed ID: 33813096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
    Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C
    Mult Scler; 2016 Oct; 22(12):1550-1559. PubMed ID: 26754800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model.
    Yeo T; Bayuangga H; Augusto-Oliveira M; Sealey M; Claridge TDW; Tanner R; Leppert D; Palace J; Kuhle J; Probert F; Anthony DC
    J Neuroinflammation; 2022 Oct; 19(1):252. PubMed ID: 36210459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    Dietmann AS; Kruse N; Stork L; Gloth M; Brück W; Metz I
    J Neurol; 2023 Mar; 270(3):1416-1429. PubMed ID: 36372867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study.
    Rise HH; Brune S; Chien C; Berge T; Bos SD; Andorrà M; Valdeolivas IP; Beyer MK; Sowa P; Scheel M; Brandt AU; Asseyer S; Blennow K; Pedersen ML; Zetterberg H; de Schotten MT; Cellerino M; Uccelli A; Paul F; Villoslada P; Harbo HF; Westlye LT; Høgestøl EA
    Neuroimage Clin; 2022; 35():103099. PubMed ID: 35772194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-1 receptor antagonist: An exploratory plasma biomarker that correlates with disability and provides pathophysiological insights in relapsing-remitting multiple sclerosis.
    Blandford SN; Galloway DA; Williams JB; Arsenault S; Brown J; MacLean G; Moore GRW; Barron J; Ploughman M; Clift F; Stefanelli M; Moore CS
    Mult Scler Relat Disord; 2021 Jul; 52():103006. PubMed ID: 34004435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chitinase 3-like 1 and neurofilament light chain in CSF and CNS atrophy in MS.
    Schneider R; Bellenberg B; Gisevius B; Hirschberg S; Sankowski R; Prinz M; Gold R; Lukas C; Haghikia A
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33172960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
    Villar LM; Picón C; Costa-Frossard L; Alenda R; García-Caldentey J; Espiño M; Muriel A; Álvarez-Cermeño JC
    Eur J Neurol; 2015 Aug; 22(8):1169-75. PubMed ID: 25324032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Morphological Study of HLA-DR-Immunopositive Cells in Multiple Sclerosis Lesions and Their Implications for Pathogenesis.
    Alturkustani M; Ang LC
    Diagnostics (Basel); 2024 Oct; 14(19):. PubMed ID: 39410644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An updated histological classification system for multiple sclerosis lesions.
    Kuhlmann T; Ludwin S; Prat A; Antel J; Brück W; Lassmann H
    Acta Neuropathol; 2017 Jan; 133(1):13-24. PubMed ID: 27988845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
    Martin SJ; McGlasson S; Hunt D; Overell J
    J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1059-1067. PubMed ID: 31123141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J
    Mult Scler; 2021 Nov; 27(13):2014-2022. PubMed ID: 33635141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
    Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extensive acute axonal damage in pediatric multiple sclerosis lesions.
    Pfeifenbring S; Bunyan RF; Metz I; Röver C; Huppke P; Gärtner J; Lucchinetti CF; Brück W
    Ann Neurol; 2015 Apr; 77(4):655-67. PubMed ID: 25612167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disentangling the heterogeneity of multiple sclerosis through identification of independent neuropathological dimensions.
    de Boer A; van den Bosch AMR; Mekkes NJ; Fransen NL; Dagkesamanskaia E; Hoekstra E; Hamann J; Smolders J; Huitinga I; Holtman IR
    Acta Neuropathol; 2024 May; 147(1):90. PubMed ID: 38771530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.